| pubmed-article:8621173 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0042769 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0166049 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0017968 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0178887 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:8621173 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:8621173 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8621173 | pubmed:dateCreated | 1996-6-19 | lld:pubmed |
| pubmed-article:8621173 | pubmed:abstractText | The significance of circulating antibody to hepatitis C virus (HCV) envelope glycoprotein 2 (E2)/nonstructural protein 1 (NS1) glycoprotein was studied in 83 patients with chronic HCV infection diagnosed by polymerase chain reaction (PCR). E2/NS1 antibody was quantitatively examined by a passive hemagglutination test using recombinant E2/NS1 glycoprotein encompassing amino acids 388 to 664 of the HCV-H strain. The results were correlated with clinical and virological features such as genotypes and viremic levels assessed by a competitive reverse-transcription PCR assay. E2/NS1 antibody was found in 73 patients (88%), and its occurrence was related to viremic levels. E2/NS1 antibody titers were low in asymptomatic HCV carriers with low levels of viral replication; 9 of 17 such patients tested positive for E2/NS1 antibody (53%), compared with 64 of 66 chronic hepatitis C patients (97%) (P < .01). A significant direct relationship was observed between viremic levels and E2/NS1 antibody titers (r = .52, P < .01). Of the 13 patients with low viremic levels of < 10(6) copies/mL, only 5 tested positive for E2/NS1 antibody (38%), whereas 68 of the 70 patients with viremic levels of > or = 10(6) copies/mL had it (97%) (P < .01). As for the relation to HCV genotypes, no difference was seen in E2/NS1 antibody titers among genotypes examined (1b, 2a, and 2b). These findings suggest that the E2/NS1 antibody tested exhibits no neutralizing activity in chronic HCV infection but may serve as a serological indicator of active virus replication. | lld:pubmed |
| pubmed-article:8621173 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8621173 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621173 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8621173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621173 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8621173 | pubmed:month | May | lld:pubmed |
| pubmed-article:8621173 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:KatayamaKK | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:KasaharaAA | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:KamadaTT | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:HayashiNN | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:OhkawaKK | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:HagiwaraHH | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:FusamotoHH | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:YukiNN | lld:pubmed |
| pubmed-article:8621173 | pubmed:author | pubmed-author:MitaEE | lld:pubmed |
| pubmed-article:8621173 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8621173 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:8621173 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8621173 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8621173 | pubmed:pagination | 947-52 | lld:pubmed |
| pubmed-article:8621173 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:meshHeading | pubmed-meshheading:8621173-... | lld:pubmed |
| pubmed-article:8621173 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8621173 | pubmed:articleTitle | Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection. | lld:pubmed |
| pubmed-article:8621173 | pubmed:affiliation | First Department of Medicine, Osaka University Medical School, Suita, Japan. | lld:pubmed |
| pubmed-article:8621173 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8621173 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8621173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8621173 | lld:pubmed |
